These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31732691)

  • 21. Enhancing Patient Safety through the Use of a Pharmaceutical Glass Designed To Prevent Cracked Containers.
    Schaut RA; Hoff KC; Demartino SE; Denson WK; Verkleeren RL
    PDA J Pharm Sci Technol; 2017; 71(6):511-528. PubMed ID: 28928290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Particulate contamination in New Zealand intravenous solutions.
    Passl WJ; Waring JM
    N Z Med J; 1980 Mar; 91(655):177-9. PubMed ID: 6929987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Balancing Container Closure Integrity and Aesthetics for a Robust Aseptic or Sterile Vial Packaging System.
    Oni Y; Song X; Schrader M; Kulshrestha A; Franck J; Asselta R; Flores-Crespo C; Mantri RV
    PDA J Pharm Sci Technol; 2019; 73(6):572-587. PubMed ID: 31101708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of particle size distribution of sub-visible particles in powder injections with different packaging forms - small-sized sub-visible particles should not be ignored.
    Wang T; Lu E; Dai Q; Huang X; Yao Q; Sha X
    Drug Dev Ind Pharm; 2023 Sep; 49(9):551-558. PubMed ID: 37647269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparing Physical Container Closure Integrity Test Methods and Artificial Leak Methodologies.
    Peláez SS; Mahler HC; Herdlitschka C; Wertli T; Kahl M; Koulov A; Matter A; Singh SK; Widmer M; Germershaus O; Mathaes R
    PDA J Pharm Sci Technol; 2019; 73(3):220-234. PubMed ID: 30651337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of factors influencing ampoule secondary particulate contamination. A strategy for its reduction in small volume parenterals.
    Bernuzzi M; Raggi P; Montanari L
    Boll Chim Farm; 1991 Sep; 130(8):323-8. PubMed ID: 1801862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Basics of Sterile Compounding: Particulate Matter.
    Akers MJ
    Int J Pharm Compd; 2017; 21(5):395-404. PubMed ID: 29216617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Materials in Manufacturing and Packaging Systems as Sources of Elemental Impurities in Packaged Drug Products: An Updated Literature Review.
    Jenke D
    PDA J Pharm Sci Technol; 2020; 74(3):324-347. PubMed ID: 31843988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Container Closure Integrity Testing-Method Development for Freeze-Dried Products Using Laser-Based Headspace Oxygen Analysis.
    Hede JO; Fosbøl PL; Berg SW; Dahl S
    PDA J Pharm Sci Technol; 2019; 73(2):170-180. PubMed ID: 30361284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Particulate and microbial contamination in in-use admixed intravenous infusions.
    Yorioka K; Oie S; Oomaki M; Imamura A; Kamiya A
    Biol Pharm Bull; 2006 Nov; 29(11):2321-3. PubMed ID: 17077539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sterile Basics of Compounding: How to Implement a Robust Visual-inspection Program.
    Summers A
    Int J Pharm Compd; 2022; 26(4):309-315. PubMed ID: 35820137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Safety of drugs: problems concerning container closures made of elastomer material for powdered and injectable drugs].
    Colombo A; Zoni G
    Boll Chim Farm; 1977 Nov; 116(11):635-6. PubMed ID: 615637
    [No Abstract]   [Full Text] [Related]  

  • 33. Sterile Basics of Compounding: Particulates in Parenteral Preparations: Sources, Minimization, and Detection.
    Allen LV
    Int J Pharm Compd; 2022; 26(3):219-228. PubMed ID: 35657746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Residual Seal Force Testing: A Suitable Method for Seal Quality Determination of (High Potent) Parenterals.
    Buecheler JW; Luemkemann J; Gieseler H; Mohl S; Streubel A
    PDA J Pharm Sci Technol; 2019; 73(2):111-120. PubMed ID: 30361287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges in the Manual Visual Inspection of the Interior Surfaces of Single-Use Systems for the Presence of Particulate Matter.
    Wormuth K; Benoit O; Kateb D; Laruelle D
    PDA J Pharm Sci Technol; 2021; 75(4):332-340. PubMed ID: 33608472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sub-visible particle quantitation in protein therapeutics.
    Cao S; Jiao N; Jiang Y; Mire-Sluis A; Narhi LO
    Pharmeur Bio Sci Notes; 2009 Oct; 2009(1):73-9. PubMed ID: 20144454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Study on insoluble microparticulate contamination at ampoule opening].
    Kawasaki Y
    Yakugaku Zasshi; 2009 Sep; 129(9):1041-7. PubMed ID: 19721379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of methods for detection of particulate matter in large-volume perenterals.
    Blanchard J; Thompson CM; Schwartz JA
    Am J Hosp Pharm; 1976 Feb; 33(2):144-50. PubMed ID: 1258874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis.
    Corvari V; Narhi LO; Spitznagel TM; Afonina N; Cao S; Cash P; Cecchini I; DeFelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Weiskopf A; Wuchner K
    Biologicals; 2015 Nov; 43(6):457-73. PubMed ID: 26324466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Industry perspective on the medical risk of visible particles in injectable drug products.
    Bukofzer S; Ayres J; Chavez A; Devera M; Miller J; Ross D; Shabushnig J; Vargo S; Watson H; Watson R
    PDA J Pharm Sci Technol; 2015; 69(1):123-39. PubMed ID: 25691720
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.